Berkeley, CA and Vancouver, BC – July 24, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, is pleased to announce that it has entered into a definitive share exchange agreement (the “Share Exchange Agreement”) with its wholly-owned subsidiary, BriaCell Therapeutics …
Berkeley, CA and Vancouver, BC – July 19, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, provided a clinical update regarding its US-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax™, a genetically engineered whole-cell vaccine derived from a human breast …
Berkeley, CA and Vancouver, BC – July 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, announced today that it has successfully manufactured a new batch of its BriaVax™ vaccine, and that this new batch has passed all release testing in compliance with recent guidelines …
Berkeley, CA and Vancouver, BC – June 1, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company announced today it has enrolled the second patient in a USA-based open-label Phase I/IIa clinical trial evaluating the safety and efficacy of BriaVax™, a genetically engineered whole-cell vaccine derived …
Berkeley, CA and Vancouver, BC – May 31, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), announced today the establishment of its Scientific Advisory Board (SAB) engaging a number of highly-experienced leading experts in the field of immune-oncology. Briacell is an immuno-oncology focused biotechnology company with a proprietary vaccine, Briavax™, …
Berkeley, CA and Vancouver, BC – May 8, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company, today announced dosing of the first patient in BriaCell’s Phase I/IIa clinical trial evaluating the Company’s lead product candidate, BriaVax™, a genetically engineered whole-cell vaccine derived from a human …
The Wall Street Analyzer Interview with Dr. Williams – 2017
Consolidated Financial Statements For the Years Ended July 31, 2016 and 2015
BERKELEY, CA and VANCOUVER, BC–(Marketwired – March 24, 2017) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX VENTURE: BCT) (OTCQB: BCTXF) is pleased to announce it has completed its previously announced non-brokered private placement financing (the “Offering”) of 5,612,083 units (the “Units”) for aggregate gross proceeds to the Company in the amount of $1,346,900 …
Berkeley, CA and Vancouver, BC – March 15, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to initiate an open-label Phase I/IIa clinical trial of BriaVaxTM in …